Inovio Treats First Patient in Immuno-Oncology Study for Advanced or Metastatic Bladder Cancer in Combination with Roche/...
PLYMOUTH MEETING, Pa., Aug. 16, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that it has dosed its first patient in a Phase 1/2a study designed to evaluate the safety, immunogenicity and clinical efficacy of INO- …